Probiotics in inflammatory bowel diseases: emphasis on mechanisms and clinical application
- Author: mycolabadmin
- 8/1/2025
- View Source
Summary
This review explores how probiotics (beneficial live bacteria) can help treat inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. Probiotics work by restoring healthy bacteria balance in the gut, strengthening the intestinal barrier, and calming the immune system’s inflammatory response. While more research is needed, particularly for Crohn’s disease, probiotics show promise as a safe, long-term treatment option that can complement standard medications and improve patients’ quality of life.
Background
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic intestinal inflammatory condition affecting quality of life. Current treatments have limitations and side effects. Probiotics have emerged as a potential adjuvant therapy for IBD management.
Objective
This review examines the mechanisms, clinical effects, and future prospects of probiotics in IBD treatment. The study synthesizes existing clinical research and experimental data to provide evidence for clinical practice and future research directions.
Results
Probiotics improve IBD symptoms through multiple mechanisms: regulating intestinal microflora, enhancing intestinal barrier function, modulating immune responses, and producing anti-inflammatory metabolites. Clinical evidence shows probiotics are more effective for ulcerative colitis than Crohn’s disease, with specific strains like Bifidobacterium and Lactobacillus showing the most promise.
Conclusion
Probiotics represent a promising adjuvant therapy for IBD with good safety profiles. Future research should focus on personalized probiotic regimens based on individual microbiota profiles, development of new probiotic strains, and combination therapies, requiring more rigorous clinical trial designs with larger sample sizes.
- Published in:Frontiers in Medicine,
- Study Type:Review,
- Source: 40823559